Form 4: Regeneron Director Arthur F. Ryan Disposes of Shares Under 10b5-1 Plan
SEC Form 4
Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. (REGN) on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Arthur F. Ryan, a director of Regeneron Pharmaceuticals, Inc., reported the disposition of common stock on October 1, 2024.
- The sales were executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on August 7, 2023.
- A total of 93 shares were sold at various prices ranging from $1,041.35 to $1,059.28.
- Following these transactions, Ryan directly owns 17,582 shares of Regeneron common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock sales by a company director under a pre-arranged trading plan, indicating a neutral sentiment.
Future Outlook
The reporting person may continue to execute transactions under the 10b5-1 trading plan.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company directors.
Stakeholder Impact
- The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 2023-08-07 | Date of adoption of the Rule 10b5-1(c) trading plan. |
| 2024-10-01 | Date of the stock sale transactions. |
| 2024-10-03 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.